Becton, Dickinson and Co (BD) has completed its acquisition of CareFusion Corp, pursuant to its previous merger agreement, the company said Tuesday.  In October 2014 BD agreed to buy CareFusion for $12.2 billion.

“This acquisition significantly accelerates BD’s strategy and builds scale and depth in medication management and patient safety solutions,” said Vincent A. Forlenza, BD’s chairman, CEO, and president.

CareFusion has become a wholly-owned subsidiary of BD and each outstanding share of common stock, par value $0.01 per share, of CareFusion was converted into the right to receive $49.00 in cash, without interest and 0.0777 of a share of common stock, par value $1.00 per share, of BD.

As a result of the completion of the acquisition, CareFusion shares will cease trading, and will be delisted from the New York Stock Exchange.

Excluding transaction-related expenses relating to the closing, BD expects the acquisition to have an immaterial impact on the Company’s results of operations in the second fiscal quarter, which ends on March 31, 2015.